Ionis Says Partner Roche Enrolls First Patient in Huntington's Disease Study

Date : 01/28/2019 @ 1:08PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 37.53  0.19 (0.51%) @ 9:38PM

Ionis Says Partner Roche Enrolls First Patient in Huntington's Disease Study

Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Ionis Pharmaceuticals Charts.

By Michael Dabaie


Ionis Pharmaceuticals Inc. (IONS) said Monday its partner Roche (RHHBY) enrolled the first patient in a pivotal study of RG6042 for Huntington's disease.

With the initiation of the study, Ionis said it earned a $35 million milestone payment.

Roche and Ionis are collaborating to develop antisense drugs to treat Huntington's disease. In total, Ionis has generated $135 million in up-front, milestone and license payments and is eligible to receive additional milestone payments as RG6042 progresses in development, as well as royalties.

Huntington's disease is a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment, Ionis said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

January 28, 2019 07:53 ET (12:53 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.